Base de dados : MEDLINE
Pesquisa : D20.215.894.860.449 [Categoria DeCS]
Referências encontradas : 332 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 34 ir para página                         

  1 / 332 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27760443
[Au] Autor:de Groot C; Müller-Goymann CC
[Ad] Endereço:Institut für Pharmazeutische Technologie, Technische Universität Braunschweig, Braunschweig, Germany.
[Ti] Título:Saponin Interactions with Model Membrane Systems - Langmuir Monolayer Studies, Hemolysis and Formation of ISCOMs.
[So] Source:Planta Med;82(18):1496-1512, 2016 Dec.
[Is] ISSN:1439-0221
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Saponins are used in medicine due to their pharmacological and immunological effects. To better understand interactions of saponins with model membranes and natural membranes of, for example, erythrocytes, Langmuir film balance experiments are well established. For most saponins, a strong interaction with cholesterol was demonstrated in dependence of both the aglycone part and the sugar moieties and is suggested to be correlated with a strong hemolytic activity, high toxicity, and high surface activity, as was demonstrated for the steroid saponin digitonin. In general, changes in the sugar chain or in substituents of the aglycone result in a modification of the saponin properties. A promising saponin with regard to fairly low hemolytic activity and high adjuvant effect is -tomatine, which still shows a high affinity for cholesterol. An interaction with cholesterol and lipids has also been proven for the Quillaja saponin from the bark of Molina. This triterpene saponin was approved in marketed vaccines as an adjuvant due to the formation of immunostimulating complexes. Immunostimulating complexes consist of a Quillaja saponin, cholesterol, phospholipids, and a corresponding antigen. Recently, another saponin from was successfully tested in immunostimulating complexes, too. Based on the results of interaction studies, the formation of drug delivery systems such as immunostimulating complexes or similar self-assembled colloids is postulated for a variety of saponins.
[Mh] Termos MeSH primário: ISCOMs/química
Saponinas/farmacologia
Tomatina/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Hemólise
Membranas Artificiais
Camundongos
Modelos Biológicos
Quillaja/química
Saponinas/química
Tomatina/química
Tomatina/isolamento & purificação
Tomatina/farmacologia
Triterpenos/química
Triterpenos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (ISCOMs); 0 (Membranes, Artificial); 0 (Saponins); 0 (Triterpenes); 0 (alpha-tomatine); 31U6547O08 (Tomatine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170428
[Lr] Data última revisão:
170428
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161021
[St] Status:MEDLINE


  2 / 332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27698563
[Au] Autor:Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
[Ad] Endereço:Institute of Biopathology and Regenerative Medicine.
[Ti] Título:Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
[So] Source:Int J Nanomedicine;11:4777-4785, 2016.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Around 20%-30% of breast cancers overexpress the proto-oncogene human epidermal growth receptor 2 (HER2), and they are characterized by being very invasive. Therefore, many current studies are focused on testing new therapies against tumors that overexpress this receptor. In particular, there exists major interest in new strategies to fight breast cancer resistant to trastuzumab (Tmab), a humanized antibody that binds specifically to HER2 interfering with its mitogenic signaling. Our team has previously developed immunostimulating complexes (ISCOMs) as nanocapsules functionalized with lipid vinyl sulfones, which can incorporate protein A and bind to G immunoglobulins that makes them very flexible nanocarriers. METHODS AND RESULTS: The aim of this in vitro study was to synthesize and evaluate a drug delivery system based on protein A-functionalized ISCOMs to target HER2-overexpressing cells. We describe the preparation of ISCOMs, the loading with the drugs doxorubicin and paclitaxel, the binding of ISCOMs to alkyl vinyl sulfone-protein A, the coupling of Tmab, and the evaluation in both HER2-overexpressing breast cancer cells (HCC1954) and non-overexpressing cells (MCF-7) by flow cytometry and fluorescence microscopy. Results show that the uptake is dependent on the level of overexpression of HER2, and the analysis of the cell viability reveals that targeted drugs are selective toward HCC1954, whereas MCF-7 cells remain unaffected. CONCLUSION: Protein A-functionalized ISCOMs are versatile carriers that can be coupled to antibodies that act as targeting agents to deliver drugs. When coupling to Tmab and loading with paclitaxel or doxorubicin, they become efficient vehicles for the selective delivery of the drug to Tmab-resistant HER2-overexpressing breast cancer cells. These nanoparticles may pave the way for the development of novel therapies for poor prognosis resistant patients.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Neoplasias da Mama/tratamento farmacológico
Sistemas de Liberação de Medicamentos/métodos
ISCOMs/química
Lipídeos/química
Receptor ErbB-2/metabolismo
Sulfonas/química
Trastuzumab/uso terapêutico
[Mh] Termos MeSH secundário: Antineoplásicos/farmacologia
Neoplasias da Mama/patologia
Morte Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Doxorrubicina/farmacologia
Doxorrubicina/uso terapêutico
Resistência a Medicamentos Antineoplásicos/efeitos dos fármacos
Endocitose/efeitos dos fármacos
Feminino
Citometria de Fluxo
Seres Humanos
Células MCF-7
Nanopartículas/química
Nanopartículas/ultraestrutura
Oxazinas/metabolismo
Paclitaxel/farmacologia
Paclitaxel/uso terapêutico
Proteína Estafilocócica A/química
Trastuzumab/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (ISCOMs); 0 (Lipids); 0 (Oxazines); 0 (Staphylococcal Protein A); 0 (Sulfones); 5PFN71LP8M (divinyl sulfone); 80168379AG (Doxorubicin); EC 2.7.10.1 (Receptor, ErbB-2); P188ANX8CK (Trastuzumab); P476F1L81G (nile red); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161005
[St] Status:MEDLINE


  3 / 332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27333763
[Au] Autor:Takahashi H; Nishibori M
[Ti] Título:[Current status and future prospects in HMGB1 and receptor researches].
[So] Source:Nihon Rinsho;74(4):703-11, 2016 Apr.
[Is] ISSN:0047-1852
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:High mobility group box protein1 (HMGB1), a ubiquitous chromatin component, is released by necrotic cells, apoptotic cells, and cells in profound distress. HMGB1 plays a critical role as a proinflammatory mediator. HMGB1 represents an important new target for drug development in a variety of inflammatory disorders, including stroke, brain injury, arteriosclerosis, and cancer. The antibodies against HMGB1 and its receptors ar hopeful candidates for immunotherapeutic strategy for treating patients with these diseases. HMGB1 forms immunostimulatory complexes by interaction with cytokines and other endogenous or exogenous factors. The HMGB1-partner molecule complexes can enhance the immune response induced by the ligand alone. The current status of HMGB1 works is summarized and future prospects will be provided in this review.
[Mh] Termos MeSH primário: Lesões Encefálicas/tratamento farmacológico
Proteína HMGB1/fisiologia
Imunoterapia
Mediadores da Inflamação
Inflamação/tratamento farmacológico
Inflamação/genética
Terapia de Alvo Molecular
Receptor para Produtos Finais de Glicação Avançada
Receptor 2 Toll-Like
Receptor 4 Toll-Like
[Mh] Termos MeSH secundário: Animais
Anticorpos/uso terapêutico
Arteriosclerose/tratamento farmacológico
Arteriosclerose/genética
Arteriosclerose/imunologia
Lesões Encefálicas/genética
Lesões Encefálicas/imunologia
Citocinas/fisiologia
Descoberta de Drogas
Proteína HMGB1/imunologia
Seres Humanos
ISCOMs
Imunoterapia/métodos
Imunoterapia/tendências
Inflamação/imunologia
Neoplasias/tratamento farmacológico
Neoplasias/genética
Neoplasias/imunologia
Acidente Vascular Cerebral/tratamento farmacológico
Acidente Vascular Cerebral/genética
Acidente Vascular Cerebral/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies); 0 (Cytokines); 0 (HMGB1 Protein); 0 (HMGB1 protein, human); 0 (ISCOMs); 0 (Inflammation Mediators); 0 (Receptor for Advanced Glycation End Products); 0 (TLR2 protein, human); 0 (TLR4 protein, human); 0 (Toll-Like Receptor 2); 0 (Toll-Like Receptor 4)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160624
[St] Status:MEDLINE


  4 / 332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Roehe, Paulo Michel
Texto completo
[PMID]:26826546
[Au] Autor:Cibulski SP; Mourglia-Ettlin G; Teixeira TF; Quirici L; Roehe PM; Ferreira F; Silveira F
[Ad] Endereço:FEPAGRO Saúde Animal, Instituto de Pesquisas Veterinárias Desidério Finamor, Laboratório de Virologia, Eldorado do Sul, RS, Brazil; Departamento de Microbiologia Imunologia e Parasitologia, Laboratório de Virologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
[Ti] Título:Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake.
[So] Source:Vaccine;34(9):1162-71, 2016 Feb 24.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In the last decades, significant efforts have been dedicated to the search for novel vaccine adjuvants. In this regard, saponins and its formulations as "immunostimulating complexes" (ISCOMs) have shown to be capable of stimulating potent humoral and cellular immune responses, enhanced cytokine production and activation of cytotoxic T cells. The immunological activity of ISCOMs formulated with a saponin fraction extracted from Quillaja brasiliensis (QB-90 fraction) as an alternative to classical ISCOMs based on Quil A(®) (IQA) is presented here. The ISCOMs prepared with QB-90, named IQB-90, typically consist of 40-50 nm, spherical, cage-like particles, built up by QB-90, cholesterol, phospholipids and antigen (ovalbumin, OVA). These nanoparticles were efficiently uptaken in vitro by murine bone marrow-derived dendritic cells. Subcutaneously inoculated IQB-90 induced strong serum antibody responses encompassing specific IgG1 and IgG2a, robust DTH reactions, significant T cell proliferation and increases in Th1 (IFN-γ and IL-2) cytokine responses. Intranasally delivered IQB-90 elicited serum IgG and IgG1, and mucosal IgA responses at distal systemic sites (nasal passages, large intestine and vaginal lumen). These results indicate that IQB-90 is a promising alternative to classic ISCOMs as vaccine adjuvants, capable of enhancing humoral and cellular immunity to levels comparable to those induced by ISCOMs manufactured with Quillaja saponaria saponins.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/farmacologia
ISCOMs/farmacologia
Imunidade Celular
Imunidade Humoral
Imunidade nas Mucosas
Saponinas de Quilaia/farmacologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/química
Administração Intranasal
Animais
Células da Medula Óssea/imunologia
Cercopithecus aethiops
Citocinas/imunologia
Células Dendríticas/imunologia
Feminino
ISCOMs/química
Imunoglobulina A/imunologia
Imunoglobulina G/sangue
Imunoglobulina G/imunologia
Injeções Subcutâneas
Ativação Linfocitária
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Nanopartículas/química
Quillaja/química
Saponinas de Quilaia/química
Coelhos
Saponinas/química
Saponinas/farmacologia
Linfócitos T Citotóxicos/imunologia
Células Vero
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Cytokines); 0 (ISCOMs); 0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (QB 90U); 0 (Quillaja Saponins); 0 (Saponins); 66594-14-7 (Quil A)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160219
[Lr] Data última revisão:
160219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160131
[St] Status:MEDLINE


  5 / 332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25307269
[Au] Autor:Pabreja S; Garg T; Rath G; Goyal AK
[Ad] Endereço:a Department of Pharmaceutics , ISF College of Pharmacy , Moga , Punjab , India.
[Ti] Título:Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes.
[So] Source:Artif Cells Nanomed Biotechnol;44(2):532-9, 2016.
[Is] ISSN:2169-141X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Tuberculosis (TB) is one of the major devastating diseases in the world, mainly caused by Mycobacterium tuberculosis. Furthermore, multi-drug resistant TB and extremely drug resistant TB are becoming big problems globally. Bacillus Calmette-Guerin (BCG) is the only available vaccine which provides protection against TB. The BCG vaccine is effective in children but not recommended in adults and elderly patients due to an associated low risk of infection with Mycobacterium tuberculosis and variable effectiveness of the vaccine. The main aim of this research study is to develop such a vaccine which will provide a better and safer profile in children and adults, as well as in elderly patients. In this present study, we prepared pulmonary tubercular vaccine by using an Antigen 85 complex (Ag85)-loaded nanocarrier such as the immunostimulating complex (ISCOM). Immunological outcomes clearly indicated significant improvement in humoral as well as cellular immune responses after pulmonary immunization with ISCOMs containing Quil A in mice.
[Mh] Termos MeSH primário: Aciltransferases/química
Aciltransferases/imunologia
Antígenos de Bactérias/química
Antígenos de Bactérias/imunologia
Portadores de Fármacos/química
ISCOMs/química
Tuberculose Pulmonar/prevenção & controle
Vacinação
[Mh] Termos MeSH secundário: Animais
Células CACO-2
Sobrevivência Celular/efeitos dos fármacos
Portadores de Fármacos/toxicidade
Liberação Controlada de Fármacos
Feminino
Hemólise/efeitos dos fármacos
Seres Humanos
ISCOMs/imunologia
ISCOMs/toxicidade
Isotipos de Imunoglobulinas/sangue
Isotipos de Imunoglobulinas/química
Camundongos
Membrana Mucosa/imunologia
Mycobacterium tuberculosis/imunologia
Mycobacterium tuberculosis/fisiologia
Nanoestruturas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Bacterial); 0 (Drug Carriers); 0 (ISCOMs); 0 (Immunoglobulin Isotypes); EC 2.3.- (Acyltransferases); EC 2.3.1.- (antigen 85A, Mycobacterium tuberculosis)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141014
[St] Status:MEDLINE
[do] DOI:10.3109/21691401.2014.966195


  6 / 332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25467890
[Au] Autor:Hecker YP; Cóceres V; Wilkowsky SE; Jaramillo Ortiz JM; Morrell EL; Verna AE; Ganuza A; Cano DB; Lischinsky L; Angel SO; Zamorano P; Odeón AC; Leunda MR; Campero CM; Morein B; Moore DP
[Ad] Endereço:Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina; Instituto Nacional de Tecnología Agropecuaria (INTA), Balcarce, CC 276, 7620 Balcarce, Argentina. Electronic address: hecker.yanina@inta.gob.ar.
[Ti] Título:A Neospora caninum vaccine using recombinant proteins fails to prevent foetal infection in pregnant cattle after experimental intravenous challenge.
[So] Source:Vet Immunol Immunopathol;162(3-4):142-53, 2014 Dec 15.
[Is] ISSN:1873-2534
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of the present study was to evaluate the immunogenicity and protective efficacy of rNcSAG1, rNcHSP20 and rNcGRA7 recombinant proteins formulated with immune stimulating complexes (ISCOMs) in pregnant heifers against vertical transmission of Neospora caninum. Twelve pregnant heifers were divided into 3 groups of 4 heifers each, receiving different formulations before mating. Immunogens were administered twice subcutaneously: group A animals were inoculated with three recombinant proteins (rNcSAG1, rNcHSP20, rNcGRA7) formulated with ISCOMs; group B animals received ISCOM-MATRIX (without antigen) and group C received sterile phosphate-buffered saline (PBS) only. The recombinant proteins were expressed in Escherichia coli and purified nickel resin. All groups were intravenously challenged with the NC-1 strain of N. caninum at Day 70 of gestation and dams slaughtered at week 17 of the experiment. Heifers from group A developed specific antibodies against rNcSAG1, rNcHSP20 and rNcGRA7 prior to the challenge. Following immunization, an statistically significant increase of antibodies against rNcSAG1 and rNcHSP20 in all animals of group A was detected compared to animals in groups B and C at weeks 5, 13 and 16 (P<0.001). Levels of antibodies against rNcGRA7 were statistical higher in group A animals when compared with groups B and C at weeks 5 and 16 (P>0.001). There were no differences in IFN-γ production among the experimental groups at any time point (P>0.05). Transplacental transmission was determined in all foetuses of groups A, B and C by Western blot, immunohistochemistry and nested PCR. This work showed that rNcSAG1, rNcHSP20 and rNcGRA7 proteins while immunogenic in cattle failed to prevent the foetal infection in pregnant cattle challenged at Day 70 of gestation.
[Mh] Termos MeSH primário: Doenças dos Bovinos/parasitologia
Coccidiose/veterinária
Transmissão Vertical de Doença Infecciosa/veterinária
Neospora/imunologia
Vacinas Protozoárias/imunologia
Vacinas Sintéticas/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antiprotozoários/sangue
Antígenos de Protozoários/genética
Antígenos de Protozoários/imunologia
Western Blotting/veterinária
Bovinos
Doenças dos Bovinos/imunologia
Doenças dos Bovinos/transmissão
Coccidiose/imunologia
Coccidiose/parasitologia
Coccidiose/transmissão
DNA de Protozoário/química
DNA de Protozoário/genética
Feminino
Feto
Proteínas de Choque Térmico HSP20/genética
Proteínas de Choque Térmico HSP20/imunologia
ISCOMs/farmacologia
Imuno-Histoquímica/veterinária
Transmissão Vertical de Doença Infecciosa/prevenção & controle
Reação em Cadeia da Polimerase/veterinária
Gravidez
Proteínas de Protozoários/genética
Proteínas de Protozoários/imunologia
Distribuição Aleatória
Estatísticas não Paramétricas
Vacinas Sintéticas/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Protozoan); 0 (Antigens, Protozoan); 0 (DNA, Protozoan); 0 (HSP20 Heat-Shock Proteins); 0 (ISCOMs); 0 (Protozoan Proteins); 0 (Protozoan Vaccines); 0 (SAG1 protein, Neospora caninum); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:141205
[Lr] Data última revisão:
141205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141204
[St] Status:MEDLINE


  7 / 332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25454469
[Au] Autor:Camussone CM; Pujato N; Renna MS; Veaute CM; Morein B; Marcipar IS; Calvinho LF
[Ad] Endereço:Estación Experimental Agropecuaria Rafaela, INTA, Santa Fe, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina.
[Ti] Título:Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant.
[So] Source:Vet Immunol Immunopathol;162(3-4):96-107, 2014 Dec 15.
[Is] ISSN:1873-2534
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Staphylococcus aureus is the most frequently isolated pathogen from bovine intramammary infections worldwide. Commercially available vaccines for mastitis control are composed either of S. aureus lysates or inactivated whole-cells formulated with traditional adjuvants. We recently showed the ability of a S. aureus CP5 lysate vaccine adjuvanted with Iscom Matrix to generate a longer lasting specific antibody response in blood and milk, with improved opsonic capacity, compared with a S. aureus CP5 whole-cell formulation. The aim of the present study was to obtain an experimental immunogen composed of lysed cells of a CP5 S. aureus strain supplemented with recombinant clumping factor A, fibronectin binding protein A and ß-toxin formulated with Iscom Matrix, characterize the immune response generated when immunizing pregnant heifers and assess the functional role of antibodies raised against this immunogen in experimental models. Both a lysate vaccine and a lysate+recombinant antigens vaccine elicited antibodies that promoted neutrophil phagocytosis and inhibited internalization into mammary epithelial cells, in vitro. Incorporation of defined antigenic molecules to the lysate formulation elicited a strong specific humoral immune response against both lysate and recombinant antigens and was associated with higher expression of regulatory and pro-inflammatory cytokines. In addition, antibodies were efficient for blocking S. aureus binding to bovine fibrinogen and fibronectin, and neutralizing ß-toxin effect in vitro, placing these antigens as candidates to be included in a formulation directed to prevent staphylococcal bovine mastitis.
[Mh] Termos MeSH primário: Imunização/veterinária
Mastite Bovina/microbiologia
Infecções Estafilocócicas/veterinária
Vacinas Antiestafilocócicas/imunologia
Staphylococcus aureus/imunologia
Vacinas Sintéticas/imunologia
[Mh] Termos MeSH secundário: Adesinas Bacterianas/genética
Adesinas Bacterianas/imunologia
Animais
Anticorpos Antibacterianos/sangue
Toxinas Bacterianas/genética
Toxinas Bacterianas/imunologia
Bovinos
Linhagem Celular
Coagulase/genética
Coagulase/imunologia
Citocinas/sangue
Feminino
Proteínas Hemolisinas/genética
Proteínas Hemolisinas/imunologia
ISCOMs/farmacologia
Imunização/métodos
Mastite Bovina/imunologia
Mastite Bovina/prevenção & controle
Leite/microbiologia
Gravidez
Distribuição Aleatória
Esfingomielina Fosfodiesterase/genética
Esfingomielina Fosfodiesterase/imunologia
Infecções Estafilocócicas/imunologia
Infecções Estafilocócicas/microbiologia
Infecções Estafilocócicas/prevenção & controle
Vacinas Antiestafilocócicas/administração & dosagem
Estatísticas não Paramétricas
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adhesins, Bacterial); 0 (Antibodies, Bacterial); 0 (Bacterial Toxins); 0 (ClfA protein, Staphylococcus aureus); 0 (Coagulase); 0 (Cytokines); 0 (Hemolysin Proteins); 0 (ISCOMs); 0 (Staphylococcal Vaccines); 0 (Vaccines, Synthetic); 0 (fibronectin-binding proteins, bacterial); EC 3.1.4.12 (Sphingomyelin Phosphodiesterase); EC 3.1.4.12 (hlb protein, Staphylococcus aureus)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:141205
[Lr] Data última revisão:
141205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141203
[St] Status:MEDLINE


  8 / 332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25203448
[Au] Autor:O'Gorman WE; Huang H; Wei YL; Davis KL; Leipold MD; Bendall SC; Kidd BA; Dekker CL; Maecker HT; Chien YH; Davis MM
[Ad] Endereço:The Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, United States.
[Ti] Título:The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors.
[So] Source:Vaccine;32(45):5989-97, 2014 Oct 14.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Seasonal influenza vaccination is one of the most common medical procedures and yet the extent to which it activates the immune system beyond inducing antibody production is not well understood. In the United States, the most prevalent formulations of the vaccine consist of degraded or "split" viral particles distributed without any adjuvants. Based on previous reports we sought to determine whether the split influenza vaccine activates innate immune receptors-specifically Toll-like receptors. High-dimensional proteomic profiling of human whole-blood using Cytometry by Time-of-Flight (CyTOF) was used to compare signaling pathway activation and cytokine production between the split influenza vaccine and a prototypical TLR response ex vivo. This analysis revealed that the split vaccine rapidly and potently activates multiple immune cell types but yields a proteomic signature quite distinct from TLR activation. Importantly, vaccine induced activity was dependent upon the presence of human sera indicating that a serum factor was necessary for vaccine-dependent immune activation. We found this serum factor to be human antibodies specific for influenza proteins and therefore immediate immune activation by the split vaccine is immune-complex dependent. These studies demonstrate that influenza virus "splitting" inactivates any potential adjuvants endogenous to influenza, such as RNA, but in previously exposed individuals can elicit a potent immune response by facilitating the rapid formation of immune complexes.
[Mh] Termos MeSH primário: Vacinas contra Influenza/imunologia
Influenza Humana/prevenção & controle
Monócitos/imunologia
Receptores de IgG/imunologia
Transdução de Sinais/imunologia
[Mh] Termos MeSH secundário: Adulto
Anticorpos Antivirais/sangue
Células Cultivadas
Citocinas/imunologia
Feminino
Proteínas Ligadas por GPI/imunologia
Seres Humanos
ISCOMs/imunologia
Imunoglobulina G/sangue
Masculino
Receptor 7 Toll-Like/agonistas
Receptor 8 Toll-Like/agonistas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Cytokines); 0 (FCGR3B protein, human); 0 (GPI-Linked Proteins); 0 (ISCOMs); 0 (Immunoglobulin G); 0 (Influenza Vaccines); 0 (Receptors, IgG); 0 (TLR7 protein, human); 0 (TLR8 protein, human); 0 (Toll-Like Receptor 7); 0 (Toll-Like Receptor 8)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140910
[St] Status:MEDLINE


  9 / 332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25130539
[Au] Autor:Sharma S; McDonald I; Miller L; Hinds LA
[Ad] Endereço:Commonwealth Scientific and Industrial Research Organisation (CSIRO), Biosecurity Flagship, GPO Box 1700, Canberra, ACT, Australia; Invasive Animals Cooperative Research Centre (IA CRC), University of Canberra, Canberra, ACT, Australia.
[Ti] Título:Parenteral administration of GnRH constructs and adjuvants: immune responses and effects on reproductive tissues of male mice.
[So] Source:Vaccine;32(43):5555-63, 2014 Sep 29.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Two gonadotrophin releasing hormone (GnRH) constructs prepared by either chemical conjugation to keyhole limpet hemocyanin (GnRH-KLH) or as an expressed recombinant fusion protein (Multimer) were evaluated with or without adjuvants (immunostimulating complexes, ISCOMs, or cytosine-phosphate-guanosine oligodeoxynucleotides, CpG ODNs). After subcutaneous administration to Balb/c male mice at Weeks 0, 2 and 4, these preparations were assessed for induction of immune responses and effects on reproductive organs. GnRH-KLH plus ISCOMs formulation induced strong IgG immune responses from Week 4 through Week 12 resulting in consistent reproductive organ atrophy by Week 12 after subcutaneous administration. GnRH-KLH plus CpG ODNs generated immune responses but no atrophy of reproductive tissues by Week 12. Multimer plus ISCOMs induced poor immune responses and no effects on reproductive tissues by Week 12. In the absence of additional adjuvant, none of the GnRH constructs induced reproductive organ atrophy. GnRH-KLH induced stronger immune responses when formulated with ISCOMs or CpG ODN compared to Multimer. GnRH-KLH with ISCOMs could be an effective colloidal alternative for emulsion GnRH vaccine formulations.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/administração & dosagem
Epididimo/patologia
Hormônio Liberador de Gonadotropina/imunologia
ISCOMs/imunologia
Oligodesoxirribonucleotídeos/imunologia
Testículo/patologia
[Mh] Termos MeSH secundário: Animais
Formação de Anticorpos
Imunoglobulina G/sangue
Masculino
Camundongos Endogâmicos BALB C
Tamanho do Órgão
Vacinas Anticoncepcionais/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (CPG-oligonucleotide); 0 (ISCOMs); 0 (Immunoglobulin G); 0 (Oligodeoxyribonucleotides); 0 (Vaccines, Contraceptive); 33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:140922
[Lr] Data última revisão:
140922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140819
[St] Status:MEDLINE


  10 / 332 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24656984
[Au] Autor:Maes D
[Ad] Endereço:Unit of Porcine Health Management,Department of Reproduction, Obstetrics and Health,Faculty of Veterinary Medicine,Ghent University,9820 Merelbeke, Belgium. Electronic address: Dominiek.Maes@UGent.be.
[Ti] Título:Vaccination against Mycoplasma hyopneumoniae infection in pigs: room for improvement.
[So] Source:Vet J;200(2):214-5, 2014 May.
[Is] ISSN:1532-2971
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/administração & dosagem
Vacinas Bacterianas/administração & dosagem
ISCOMs/administração & dosagem
Mycoplasma hyopneumoniae/imunologia
Pneumonia Suína Micoplasmática/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Feminino
Masculino
[Pt] Tipo de publicação:COMMENT; EDITORIAL
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Bacterial Vaccines); 0 (ISCOMs)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:140512
[Lr] Data última revisão:
140512
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140325
[St] Status:MEDLINE



página 1 de 34 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde